These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 17062320)

  • 1. Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial.
    Mohamed S; Osatuke K; Aslam M; Kasckow J
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):201-9. PubMed ID: 17062320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder.
    Stein DJ; Lopez AG
    Adv Ther; 2011 Nov; 28(11):1021-37. PubMed ID: 22057726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.
    Davidson JR; Bose A; Korotzer A; Zheng H
    Depress Anxiety; 2004; 19(4):234-40. PubMed ID: 15274172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
    Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder.
    Pollack M; Kinrys G; Krystal A; McCall WV; Roth T; Schaefer K; Rubens R; Roach J; Huang H; Krishnan R
    Arch Gen Psychiatry; 2008 May; 65(5):551-62. PubMed ID: 18458207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Escitalopram for treatment of major depressive disorder in adults].
    Llorca PM; Brousse G; Schwan R
    Encephale; 2005; 31(4 Pt 1):490-501. PubMed ID: 16389716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder.
    Davidson JR; Bose A; Wang Q
    J Clin Psychiatry; 2005 Nov; 66(11):1441-6. PubMed ID: 16420082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
    Mao PX; Tang YL; Jiang F; Shu L; Gu X; Li M; Qian M; Ma C; Mitchell PB; Cai ZJ
    Depress Anxiety; 2008; 25(1):46-54. PubMed ID: 17149753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence.
    Muhonen LH; Lönnqvist J; Juva K; Alho H
    J Clin Psychiatry; 2008 Mar; 69(3):392-9. PubMed ID: 18348597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
    Kennedy SH; Andersen HF; Lam RW
    J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of escitalopram in treatment of severe depression in Chinese population.
    Si T; Wang G; Yang F; Fang Y; Fang M; Li J; Dong J; Shen X; Zhuo J; Rui Q; Wang J; Cuili H
    Metab Brain Dis; 2017 Jun; 32(3):891-901. PubMed ID: 28299626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
    Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
    J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder.
    Kim EY; Kim SH; Lee HJ; Lee NY; Kim HY; Park CHK; Ahn YM
    J Affect Disord; 2019 Dec; 259():91-97. PubMed ID: 31445345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.